专题报道:骨科

免疫细胞相关因子介导的骨稳态失衡及其在骨相关疾病中的研究进展

  • 刘洋 ,
  • 程畅波 ,
  • 卢鸿铎 ,
  • 陈犇璐 ,
  • 陈志文 ,
  • 陈镇秋 ,
  • 凡一诺
展开
  • 1.广州中医药大学第一临床医学院 (广东 广州 510499 )
    2.广州中医药大学岭南医学研究中心 (广东 广州 510388 )
    3.广州中医药大学第三附属医院 (广东 广州 510378 )
    4.中医证候全国重点实验室 (广东 广州 510000 )
    5.广州中医药大学第一附属医院骨伤中心股骨头坏死科 (广东 广州 510405 )

收稿日期: 2025-09-22

  修回日期: 2025-11-19

  录用日期: 2025-11-25

  网络出版日期: 2026-01-22

基金资助

国家自然科学基金面上项目(82374475);中医证候全国重点实验室开放课题重点项目(SKLKY2024B0004Z)

Research progress on immune cells and related cytokines mediated imbalance of bone homeostasis and its roles in bone-related diseases

  • Yang LIU ,
  • Changbo CHENG ,
  • Hongduo LU ,
  • Benlu CHEN ,
  • Zhiwen CHEN ,
  • Zhenqiu CHEN ,
  • Yinuo FAN
Expand
  • 1.The first Clinical Medical College of Guangzhou University of Traditional Chinese Medicine,Guangzhou 510499,Guangdong,China
    2.Lingnan Medical Research Center of Guangzhou University of Chinese Medicine,Guangzhou 510388,Guangdong,China
    3.The Third Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510378,Guangdong,China
    4.State Key Laboratory of Traditional Chinese Medicine Syndrome,Guangzhou 510000,Guangdong,China
    5.Department of Femoral Head Necrosis,Bone Injury Center,First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510405,Guangdong,China

Received date: 2025-09-22

  Revised date: 2025-11-19

  Accepted date: 2025-11-25

  Online published: 2026-01-22

摘要

骨稳态的平衡对于维持骨骼健康而言非常关键,它涉及到由成骨细胞所介导的骨形成以及由破骨细胞所介导的骨吸收,近些年来,随着骨免疫学(osteoimmunology)研究的深入,免疫细胞相关因子在骨稳态里的作用日益受到人们的关注,大量证据表明,白细胞介素(interleukins, ILs)、肿瘤坏死因子(tumor necrosis factors, TNFs)、干扰素(interferons, IFNs)等细胞因子不仅参与免疫应答,还通过影响成骨细胞分化、破骨细胞生成及其活性,直接或间接地调控骨重建过程。然而,目前针对免疫细胞因子与骨稳态关系的系统性总结仍相对匮乏,尤其是在不同因子作用机制、信号通路及其在骨相关疾病(如骨质疏松、类风湿性关节炎、骨关节炎等)中的病理角色方面,尚缺乏全面的综述与整合分析。该文拟对免疫细胞相关因子对骨稳态的影响展开综述,重点探讨其对成骨细胞与破骨细胞功能的调节机制,并结合最新研究进展分析这些因子在骨稳态相关疾病发生发展中的作用。旨在为深入理解骨免疫调控网络及骨代谢疾病的防治提供理论依据与潜在的干预靶点。

本文引用格式

刘洋 , 程畅波 , 卢鸿铎 , 陈犇璐 , 陈志文 , 陈镇秋 , 凡一诺 . 免疫细胞相关因子介导的骨稳态失衡及其在骨相关疾病中的研究进展[J]. 实用医学杂志, 2026 , 42(2) : 276 -284 . DOI: 10.3969/j.issn.1006-5725.2026.02.013

Abstract

The equilibrium of bone homeostasis is crucial for sustaining skeletal health, which depends on the precise regulation between bone formation mediated by osteoblasts and bone resorption mediated by osteoclasts. In recent years, with the progress of osteoimmunology research, more and more attention has been devoted to the role of immune cell?derived factors in bone homeostasis. A growing amount of evidence demonstrates that cytokines such as interleukins (ILs), tumor necrosis factors (TNFs), and interferons (IFNs) not only take part in immune responses but also directly or indirectly regulate bone remodeling by affecting osteoblast differentiation, osteoclastogenesis, and osteoclast activity. However, systematic summaries that address the relationship between immune cell-derived cytokines and bone homeostasis are still relatively scarce. This is especially true when it comes to the mechanisms of action, signaling pathways, and pathological roles of different cytokines in bone-related diseases such as osteoporosis, rheumatoid arthritis, and osteoarthritis. This review intends to comprehensively investigate the effects of immune cell-derived cytokines, including interleukins, tumor necrosis factors, and interferons, on bone homeostasis, with an emphasis on their regulatory mechanisms in osteoblast and osteoclast function. Moreover, it will incorporate the latest research progress to analyze the participation of these cytokines in the onset and progression of bone homeostasis-related diseases, thus offering a theoretical foundation and potential therapeutic targets for the prevention and treatment of bone metabolic disorders.

参考文献

[1] WANG L, YOU X, ZHANG L, et al. Mechanical regulation of bone remodeling [J]. Bone Res, 2022, 10(1): 16. doi: 10.1038/s41413-022-00190-4 .
[2] ADAMOPOULOS I E, CHOI Y, TAKAYANAGI H. Novel insights and recent progress in osteoimmunology [J]. Trends Immunol, 2025, 46(3): 192-194. doi: 10.1016/j.it.2025.02.003 .
[3] DENG A F, WANG F X, WANG S C, et al. Bone-organ axes: Bidirectional crosstalk [J]. Mil Med Res, 2024, 11(1): 37. doi: 10.1186/s40779-024-00540-9 .
[4] CHANDRABALAN S, DANG L, HANSEN U, et al. A novel method to efficiently differentiate human osteoclasts from blood-derived monocytes [J]. Biol Proced Online, 2024, 26(1): 7. doi: 10.1186/s12575-024-00233-6 .
[5] OH W T, YANG Y S, XIE J, et al. Wnt-modulating gene silencers as a gene therapy for osteoporosis, bone fracture, and critical-sized bone defects [J]. Mol Ther, 2023, 31(2): 435-453. doi: 10.1016/j.ymthe.2022.09.018 .
[6] WU M, WU S, CHEN W, et al. The roles and regulatory mechanisms of tgf-beta and bmp signaling in bone and cartilage development, homeostasis and disease [J]. Cell Res, 2024, 34(2): 101-123. doi: 10.1038/s41422-023-00918-9 .
[7] HU G, YU Y, SHARMA D, et al. Glutathione limits runx2 oxidation and degradation to regulate bone formation [J]. JCI Insight, 2023, 8(16). doi: 10.1172/jci.insight.166888 .
[8] ZHENG Z, TAO S, JIN J, et al. Rkip regulates bone marrow macrophage differentiation to mediate osteoclastogenesis and h-type vessel formation [J]. Nat Commun, 2025, 16(1): 7604. doi: 10.1038/s41467-025-62972-8 .
[9] 胡康一, 宋永嘉, 文皓楠, 等. 骨免疫学:T细胞在骨代谢调控中的双向作用 [J]. 中国骨质疏松杂志, 2025, 31(6): 885-891. doi: 10.3969/j.issn.1006-7108.2025.06.017 .
[10] 张玉红, 单新洁, 周俊. Mir-155通过Socs1/Stat3途径调控类风湿性关节炎中炎症反应和Th17/Treg失衡 [J]. 实用医学杂志, 2024, 40(13): 1791-1796. doi: 10.3969/j.issn.1006-5725. 2024.13.005 .
[11] SAPRA L, BHARDWAJ A, MISHRA P K, et al. Regulatory b cells (bregs) inhibit osteoclastogenesis and play a potential role in ameliorating ovariectomy-induced bone loss [J]. Front Immunol, 2021, 12: 691081. doi: 10.3389/fimmu.2021.691081 .
[12] GARLANDA C, DI CEGLIE I, JAILLON S. Il-1 family cytokines in inflammation and immunity [J]. Cell Mol Immunol, 2025, 22(11): 1345-1362. doi: 10.1038/s41423-025-01358-8 .
[13] FUKAWA Y, KAYAMORI K, TSUCHIYA M, et al. Il-1 generated by oral squamous cell carcinoma stimulates tumor-induced and rankl-induced osteoclastogenesis: A possible mechanism of bone resorption induced by the infiltration of oral squamous cell carcinoma [J]. Int J Mol Sci, 2022, 24(1):688. doi: 10.3390/ijms24010688 .
[14] WANG H, NI Z, YANG J, et al. Il-1beta promotes osteogenic differentiation of mouse bone marrow mesenchymal stem cells via the bmp/smad pathway within a certain concentration range [J]. Exp Ther Med, 2020, 20(4): 3001-3008. doi: 10.3892/etm. 2020. 9065 .
[15] TAKEUCHI T, YOSHIDA H, TANAKA S. Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis [J]. Autoimmun Rev, 2021, 20(9): 102884. doi: 10.1016/j.autrev. 2021. 102884 .
[16] ZHANG Y, LI X, CHIHARA T, et al. Effect of tnf-alpha and il-6 on compact bone-derived cells [J]. Tissue Eng Regen Med, 2021, 18(3): 441-451. doi: 10.1007/s13770-021-00336-1 .
[17] PALMISANO B, RIMINUCCI M, KARSENTY G. Interleukin-6 signaling in osteoblasts regulates bone remodeling during exercise [J]. Bone, 2023, 176: 116870. doi: 10.1016/j.bone.2023. 116870 .
[18] TANG H, ZHU S, CHEN K, et al. Il-17a regulates autophagy and promotes osteoclast differentiation through the erk/mtor/beclin1 pathway [J]. PLoS One, 2023, 18(2): e281845. doi: 10.1371/journal.pone.0281845 .
[19] LEE K T, LIN C Y, LIU S C, et al. Il-17 promotes il-18 production via the mek/erk/mir-4492 axis in osteoarthritis synovial fibroblasts [J]. Aging (Albany Ny), 2024, 16(2): 1829-1844. doi: 10.18632/aging.205462 .
[20] AL-QAHTANI F, ALQHTANI N, DIVAKAR D D, et al. Levels of whole salivary advanced glycation end products and interleukin-17 and peri-implant clinical and radiographic status in patients with osteoporosis at 6-years' follow-up [J]. BMC Oral Health, 2022, 22(1): 526. doi: 10.1186/s12903-022-02591-7 .
[21] JANG D I, LEE A H, SHIN H Y, et al. The role of tumor necrosis factor alpha (tnf-alpha) in autoimmune disease and current tnf-alpha inhibitors in therapeutics [J]. Int J Mol Sci, 2021, 22(5):2719. doi: 10.3390/ijms22052719 .
[22] MARAHLEH A, KITAURA H, OHORI F, et al. Tnf-alpha directly enhances osteocyte rankl expression and promotes osteoclast formation [J]. Front Immunol, 2019, 10: 2925. doi: 10.3389/fimmu.2019.02925 .
[23] WANG S, ZHANG H, ZHU Y, et al. Progranulin protects against osteoporosis by regulating osteoclast and osteoblast balance via tnfr pathway [J]. J Cell Mol Med, 2025, 29(3): e70385. doi: 10.1111/jcmm.70385 .
[24] WONG C W, HUANG Y Y, HURLSTONE A. The role of ifn-gamma-signalling in response to immune checkpoint blockade therapy [J]. Essays Biochem, 2023, 67(6): 991-1002. doi: 10.1042/ EBC20230001 .
[25] WANG H, JOSHI P, HONG S H, et al. Predicting the targets of irf8 and nfatc1 during osteoclast differentiation using the machine learning method framework ctap [J]. BMC Genomics, 2022, 23(1): 14. doi: 10.1186/s12864-021-08159-z .
[26] PLACE D E, MALIREDDI R, KIM J, et al. Osteoclast fusion and bone loss are restricted by interferon inducible guanylate binding proteins [J]. Nat Commun, 2021, 12(1): 496. doi: 10.1038/ s41467-020-20807-8 .
[27] GILBERT S J, BLAIN E J, MASON D J. Interferon-gamma modulates articular chondrocyte and osteoblast metabolism through protein kinase r-independent and dependent mechanisms [J]. Biochem Biophys Rep, 2022, 32: 101323. doi: 10.1016/j.bbrep.2022.101323 .
[28] DAMAN A W, JOSEFOWICZ S Z. Epigenetic and transcriptional control of interferon-beta [J]. J Exp Med, 2021, 218(9):e20210039. doi: 10.1084/jem.20210039 .
[29] 王梦蝶, 吴虹, 王荣慧, 等. Rankl介导的诱导破骨细胞分化的相关经典信号通路研究进展 [J]. 中国药理学通报, 2020, 36(7): 898-902. doi: 10.3969/j.issn.1001-1978.2020.07.003 .
[30] LIU X, ZHANG L, WANG G, et al. Single-cell transcriptome profiling identifies the activation of type i interferon signaling in ossified posterior longitudinal ligament [J]. Front Med, 2024, 18(6): 1087-1099. doi: 10.1007/s11684-024-1075-5 .
[31] DENG Z, FAN T, XIAO C, et al. Tgf-beta signaling in health, disease, and therapeutics [J]. Signal Transduct Target Ther, 2024, 9(1): 61. doi: 10.1038/s41392-024-01764-w .
[32] LIU Y, ZHAO L, LI M, et al. Osteocytes produces rankl via wnt-tgfbeta signaling axis for osteoclastogenesis [J]. Int J Biol Sci, 2025, 21(13): 5821-5841. doi: 10.7150/ijbs.117481 .
[33] 张慎启, 石磊, 李文金, 等. 骨质疏松相关骨免疫学进展 [J]. 中国老年学杂志, 2021, 41(13): 2907-2912. doi: 10.3969/j.issn.1005-9202.2021.13.062 .
[34] XU J, YU L, LIU F, et al. The effect of cytokines on osteoblasts and osteoclasts in bone remodeling in osteoporosis: A review [J]. Front Immunol, 2023, 14: 1222129. doi: 10.3389/fimmu.2023. 1222129 .
[35] ZHIVODERNIKOV I V, KIRICHENKO T V, MARKINA Y V, et al. Molecular and cellular mechanisms of osteoporosis [J]. Int J Mol Sci, 2023, 24(21): 15772. doi: 10.3390/ijms242115772 .
[36] CHEN M, FU W, XU H, et al. Pathogenic mechanisms of glucocorticoid-induced osteoporosis [J]. Cytokine Growth Factor Rev, 2023, 70: 54-66. doi: 10.1016/j.cytogfr.2023.03.002 .
[37] RONG X, KOU Y, ZHANG Y, et al. Ed-71 prevents glucocorticoid-induced osteoporosis by regulating osteoblast differentiation via notch and wnt/beta-catenin pathways [J]. Drug Des Devel Ther, 2022, 16: 3929-3946. doi: 10.2147/DDDT.S377001 .
[38] 姜楠, 田新平, 曾小峰. 《2024中国类风湿关节炎诊疗指南》解读 [J]. 协和医学杂志, 2025, 16(1): 28-34. doi: 10.12290/xhyxzz.2024-1018 .
[39] KONDO N, KURODA T, KOBAYASHI D. Cytokine networks in the pathogenesis of rheumatoid arthritis [J]. Int J Mol Sci, 2021, 22(20):10922. doi: 10.3390/ijms222010922 .
[40] 邱安琪. 细胞因子在类风湿关节炎发病机制中的研究进展 [J]. 检验医学与临床, 2023, 20(6): 830-834. doi: 10.3969/j.issn.1672-9455.2023.06.028 .
[41] YOKOTA K, SATO K, MIYAZAKI T, et al. Characterization and function of tumor necrosis factor and interleukin-6-induced osteoclasts in rheumatoid arthritis [J]. Arthritis Rheumatol, 2021, 73(7): 1145-1154. doi: 10.1002/art.41666 .
[42] 中国微循环学会骨微循环专业委员会. 股骨头坏死临床诊疗技术专家共识(2022 年) [J]. 中国修复重建外科杂志, 2022, 36(11): 1319-1326. doi: 10.7507/1002-1892.202207134 .
[43] 杨晓强, 廖家如, 林锟, 等. 基于单细胞转录组学探索激素性股骨头坏死囊性变内皮细胞的转录特征及活血通络法的干预作用 [J]. 中华中医药杂志, 2025, 40(6): 2838-2845.
[44] ZHENG L W, WANG W C, MAO X Z, et al. Tnf-alpha regulates the early development of avascular necrosis of the femoral head by mediating osteoblast autophagy and apoptosis via the p38 mapk/nf-kappab signaling pathway [J]. Cell Biol Int, 2020, 44(9): 1881-1889. doi: 10.1002/cbin.11394 .
[45] MA J, GE J, GAO F, et al. The role of immune regulatory cells in nontraumatic osteonecrosis of the femoral head: A retrospective clinical study [J]. Biomed Res Int, 2019, 2019: 1302015. doi: 10.1155/2019/1302015 .
[46] 孟志成, 乔卫平, 赵阳, 等. 免疫细胞及相关细胞因子在骨关节炎发病及治疗中的作用 [J]. 中国组织工程研究, 2024, 28(2): 280-287. doi: 10.12307/2023.679 .
[47] 董勇勇, 段广斌, 茹嘉, 等. 膝关节骨性关节炎患者血清Il-1Β、Tnf-Α表达及其与术后疼痛指标的关系 [J]. 中国实用医刊, 2022, 49(18): 54-57. doi: 10.3760/cma.j.cn115689-20220611-02484 .
[48] DEFOIS A, BON N, CHARPENTIER A, et al. Osteoarthritic chondrocytes undergo a glycolysis-related metabolic switch upon exposure to il-1b or tnf [J]. Cell Commun Signal, 2023, 21(1): 137. doi: 10.1186/s12964-023-01150-z .
[49] SUN G, BA C L, GAO R, et al. Association of il-6, il-8, mmp-13 gene polymorphisms with knee osteoarthritis susceptibility in the chinese han population [J]. Biosci Rep, 2019, 39(2):BSR20181346. doi: 10.1042/BSR20181346 .
[50] FANG C, ZHONG R, LU S, et al. Trem2 promotes macrophage polarization from m1 to m2 and suppresses osteoarthritis through the nf-kappab/cxcl3 axis [J]. Int J Biol Sci, 2024, 20(6): 1992-2007. doi: 10.7150/ijbs.91519 .
[51] 王郡, 孟娟. 类风湿关节炎靶向治疗新时代 [J]. 协和医学杂志, 2025, 16(1): 19-27. doi: 10.12290/xhyxzz.2024-0842 .
[52] ZHENG X, WU Y, BI J, et al. The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy [J]. Cell Mol Immunol, 2022, 19(2): 192-209. doi: 10.1038/s41423-021-00786-6 .
文章导航

/